Former riociguat 2.5 mg maximum | Former riociguat 1.5 mg maximum | Placebo | Total population PATENT-2 1 year | |||||||
PATENT-1 week 12 | PATENT-2 | PATENT-1 week 12 | PATENT-2 | PATENT-1 week 12 | PATENT-2 | |||||
Week 12 | 1 year | Week 12 | 1 year | Week 12 | 1 year | |||||
NT-proBNP | ||||||||||
Observed values pg mL-1 | −338±1031 | −322±1206 | −291±1612 | −447±954 | −520±944 | −235±1214 | 134±809 | −410±1023 | −294±1945 | −284±1653 |
Patients | 207 | 201 | 177 | 46 | 46 | 44 | 95 | 93 | 80 | 301 |
Borg dyspnoea score | ||||||||||
Observed values | −0.55±1.52 | −0.58±1.84 | −0.52±1.98 | −0.43±1.19 | −0.52±1.64 | −0.18±1.58 | −0.15±1.88 | −0.54±1.90 | −0.45±2.06 | −0.45±1.94 |
Patients | 228 | 218 | 192 | 55 | 54 | 49 | 108 | 102 | 84 | 325 |
EQ-5D score | ||||||||||
Observed values | 0.05±0.21 | 0.06±0.22 | 0.06±0.24 | 0.10±0.26 | 0.15±0.24 | 0.13±0.24 | 0.02±0.22 | 0.03±0.24 | 0.07±0.20 | 0.07±0.23 |
Patients | 227 | 212 | 193 | 55 | 52 | 50 | 106 | 102 | 83 | 326 |
LPH score | ||||||||||
Observed values | −7.6±16.8 | −11.0±18.9 | −11.8±16.1 | −14.3±18.9 | −2.7±15.1 | −2.1±15.7 | ||||
Patients | 224 | 209# | 55 | 54# | 105 | 93# |
Data are presented as mean±sd or n. NT-proBNP: N-terminal prohormone of brain natriuretic peptide; EQ-5D: Euro Qol Group 5-Dimension Self-Report Questionnaire. #: Week 8 data shown for Living with Pulmonary Hypertension (LPH) score.